Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury

Trial Profile

Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Acronyms LAKIS
  • Most Recent Events

    • 27 Oct 2016 Planned number of patients changed from 64 to 68.
    • 26 Sep 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2017.
    • 09 Dec 2015 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top